From allergen genes to allergy vaccines

Annual Review of Immunology

Volumn 28, Issue , 2010, Pages 211-241

  Valenta, Rudolf ^a   Ferreira, Fatima ^b   Focke Tejkl, Margarete ^a   Linhart, Birgit ^a   Niederberger, Verena ^a   Swoboda, Ines ^a   Vrtala, Susanne ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Allergy; Diagnosis; IgE; Peptide; Recombinant allergen; Specific immunotherapy; T cell

Indexed keywords

BEE VENOM; EPITOPE; HAPTEN; HYBRID PROTEIN; IMMUNOGLOBULIN E; PEPTIDE VACCINE; POLLEN ANTIGEN; RAGWEED ANTIGEN; RECOMBINANT ALLERGEN; ALLERGEN; VACCINE;

ALLERGY; ANTIBODY RESPONSE; B LYMPHOCYTE; BEE STING; CELLULAR IMMUNITY; GENE THERAPY; GENETIC IMMUNIZATION; GRASS POLLEN; HUMAN; HUMORAL IMMUNITY; HYBRID; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; MOLECULAR RECOGNITION; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T LYMPHOCYTE; WILD TYPE; ANIMAL; CHEMISTRY; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY;

ALLERGENS; ANIMALS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; VACCINES;

EID: 77952301906     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-030409-101218     Document Type: Review

References (242)

1. Kay A. 2008. Allergy and Allergic Diseases. Oxford: Blackwell Sci.
2. Kulig M, Bergmann R, Klettke U, Wahn V, Tacke U, Wahn U. 1999. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J. Allergy Clin. Immunol. 103:1173-1179
3. Niederberger V, NiggemannB, Kraft D, Spitzauer S, Valenta R. 2002. Evolution of IgM, IgE and IgG(1-4) antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms. Eur. J. Immunol. 32:576-584
4. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. 1990. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N. Engl. J. Med. 323:502-507
5. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. 2001. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 357:752-756
6. Braun-Fahrländer C, Riedler J, Herz U, Eder W, Waser M, et al. 2002. Environmental exposure to endotoxin and its relation to asthma in school-age children. N. Engl. J. Med. 347:869-877
7. Romagnani S. 1994. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 12:227-257
8. Stern DA, Riedler J, Nowak D, Braun-Fahrländer C, Swoboda I, et al. 2007. Exposure to a farming environment has allergen-specific protective effects on TH2-dependent isotype switching in response to common inhalants. J. Allergy Clin. Immunol. 119:351-358
9. Snapper CM, Paul WE. 1987. Interferon-γ andBcell stimulatory factor-1 reciprocally regulateIg isotype production. Science 236:944-947
10. Brown MA, Pierce JH, Watson CJ, Falco J, Ihle JN, Paul WE. 1987. B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell 50:809-818
11. Ishizaka K, Ishizaka T, Hornbrook MM. 1966. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J. Immunol. 97:75-85
12. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, et al. 2003. The biology of IGE and the basis of allergic disease. Annu. Rev. Immunol. 21:579-628
13. Bischoff SC. 2007. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat. Rev. Immunol. 7:93-104
14. Mudde GC, Van Reijsen FC, Boland GJ, de Gast GC, Bruijnzeel PL, Bruijnzeel-Koomen CA. 1990. Allergen presentation by epidermal Langerhans' cells from patients with atopic dermatitis is mediated by IgE. Immunology 69:335-341
15. van der Heijden FL, Joost van Neerven RJ, van Katwijk M, Bos JD, Kapsenberg ML. 1993. Serum-IgE-facilitated allergen presentation in atopic disease. J. Immunol. 150:3643-3650
16. Naclerio RM, Adkinson NF Jr, Moylan B, Baroody FM, Proud D, et al. 1997. Nasal provocation with allergen induces a secondary serum IgE antibody response. J. Allergy Clin. Immunol. 100:505-510
17. Chakir J, Laviolette M, Turcotte H, Boutet M, Boulet LP. 2000. Cytokine expression in the lower airways of nonasthmatic subjects with allergic rhinitis: influence of natural allergen exposure. J. Allergy Clin. Immunol. 106:904-910
18. Niederberger V, Ring J, Rakoski J, Jager S, Spitzauer S, et al. 2007. Antigens drive memory IgE responses in human allergy via the nasal mucosa. Int. Arch. Allergy Immunol. 142:133-144
19. Noon L. 1911. Prophylactic inoculation against hay fever. Lancet 1:1572-1573
20. Larché M, Akdis CA, Valenta R. 2006. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6:761-771
21. Cooke RA, Barnard JH, Hebald S, Stull A. 1935. Serological evidence of immunity with coexisting sensitization in a type of human allergy. J. Exp. Med. 62:733-750
22. Loveless MH. 1940. Immunological studies of pollinosis. I. The presence of two antibodies related to the same pollen antigen in the serum of treated hay-fever patients. J. Immunol. 38:25-50
23. Valenta R, Ball T, Focke M, Linhart B, Mothes N, et al. 2004. Immunotherapy of allergic disease. Adv. Immunol. 82:105-153
24. Bousquet J, Lockey R, Malling HJ. 1998. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102:558-562
25. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, et al. 1999. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341:468-475
26. Mö ller C, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. 2002. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol. 109:251-256
27. Johnson P, Marsh DG. 1965. 'Isoallergens' from rye grass pollen. Nature 206:935-937
28. Berrens L. 1971. The chemistry of atopic allergens. Monogr. Allergy 7:1-298
29. Chapman MD, Platts-Mills TA. 1980. Purification and characterization of the major allergen from Dermatophagoides pteronyssinus-antigen P1. J. Immunol. 125:587-592
30. Sehon AH, Kraft D, Kunkel G. 1990. Epitopes of Atopic Allergens. Brussels: UCB Inst. Allergy
31. Fang KS, Vitale M, Fehlner P, King TP. 1988. cDNA cloning and primary structure of a white-face hornet venom allergen, antigen 5. Proc. Natl. Acad. Sci. USA 85:895-899
32. Chua KY, Stewart GA, Thomas WR, Simpson RJ, Dilworth RJ, et al. 1988. Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases. J. Exp. Med. 167:175-82
33. Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, et al. 1989. The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J. 8:1935-1938
34. Valenta R, Kraft D. 2001. Recombinant allergen molecules: tools to study effector cell activation. Immunol. Rev. 179:119-127
35. Valenta R. 2008. Biochemistry of allergens, recombinant allergens. In Allergy and Allergic Diseases, ed. AB Kay, A Kaplan, J Bousquet, P Holt, pp. 898-912. Oxford: Blackwell. 2nd ed
36. Mari A. 2005. Importanceofdatabasesinexperimental and clinical allergology. Int. Arch. Allergy Immunol. 138:88-96
37. + T cell clones. J. Immunol. 148:738-745
38. Ebner C, Schenk S, Szépfalusi Z, Hoffmann K, Ferreira F, et al. 1993. Multiple T cell specificities for Bet v I, the major birch pollen allergen, within single individuals. Studies using specific T cell clones and overlapping peptides. Eur. J. Immunol. 23:1523-1527 (Pubitemid 23218059)
39. van Neerven RJ, van de Pol MM, Wierenga EA, Aalberse RC, Jansen HM, Kapsenberg ML. 1994. Peptide specificity and HLA restriction do not dictate lymphokine production by allergen-specific T-lymphocyte clones. Immunology 82:351-356
40. O'Hehir RE, Eckels DD, Frew AJ, Kay AB, Lamb JR. 1988. MHC class II restriction specificity of cloned human T lymphocytes reactive with Dermatophagoides farinae (house dust mite). Immunology 64:627-631
41. Sallusto F, Corinti S, Pini C, Biocca MM, Bruno G, Di Felice G. 1996. Parietaria judaica-specific T-cell clones from atopic patients: heterogeneity in restriction, V beta usage, and cytokine profile. J. Allergy Clin. Immunol. 97:627-637
42. Sone T, Morikubo K, Miyahara M, Komiyama N, Shimizu K, et al. 1998. T cell epitopes in Japanese cedar (Cryptomeria japonica) pollen allergens: choice of major T cell epitopes in Cry j 1 and Cry j 2 toward designofthe peptide-based immunotherapeutics for the managementofJapanese cedar pollinosis. J. Immunol. 161:448-457
43. Würtzen P, Wissenbach M, Ipsen H, Bufe A, Arnved J, van Neerven RJ. 1999. Highly heterogeneous Phl p 5-specific T cells from patients with allergic rhinitis differentially recognize recombinant Phl p 5 isoallergens. J. Allergy Clin. Immunol. 104:115-122
44. Huang SK, Yi M, Palmer E, Marsh DG. 1995. A dominant T cell receptor beta-chain in response to a short ragweed allergen, Amb a 5. J. Immunol. 154:6157-6162
45. Huang SK, Zwollo P, Marsh DG. 1991. Class II major histocompatibility complex restriction of human T cell responses to short ragweed allergen, Amb a V. Eur. J. Immunol. 21:1469-1473
46. *01. J. Allergy Clin. Immunol. 115:399-404
47. van Reijsen FC, Bruijnzeel-Koomen CA, de Weger RA, Mudde GC. 1997. Retention of long-lived, allergen-specific T cells in atopic dermatitis skin\letter. J. Investig. Dermatol. 108:530
48. Bohle B, Schwihla H, Hu HZ, Friedl-Hajek R, Sowka S, et al. 1998. Long-lived Th2 clones specific for seasonal and perennial allergens can be detected in blood and skin by their TCR-hypervariable regions. J. Immunol. 160:2022-2027
49. Wierenga EA, Snoek M, Bos JD, Jansen HM, Kapsenberg ML. 1990. Comparison of diversity and function of house dust mite-specific T lymphocyte clones from atopic and non-atopic donors. Eur. J. Immunol. 20:1519-1526
50. van Neerven RJ, van de Pol MM, van Milligen FJ, Jansen HM, Aalberse RC, Kapsenberg ML. 1994. Characterization of cat dander-specific T lymphocytes from atopic patients. J. Immunol. 152:4203-4210
51. Ebner C, Schenk S, Najafian N, Siemann U, Steiner R, et al. 1995. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J. Immunol. 154:1932-1940
52. + T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J. Immunol. 180:4514-4522
53. Tordesillas L, Cuesta-Herranz J, Gonzalez-Muñoz M, Pacios LF, Compés E, et al. 2009. T-cell epitopes of the major peach allergen, Pru p 3: identification and differential T-cell response of peach-allergic and non-allergic subjects. Mol. Immunol. 46:722-28
54. + regulatory T cells in children who have outgrown cow's milk allergy. J. Exp. Med. 199:1679-1688
55. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, et al. 2004. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J. Exp. Med. 199:1567-1575
56. Shreffler WG, Wanich N, MoloneyM, Nowak-WegrzynA, Sampson HA. 2009. Associationofallergen-specific regulatory T cells with the onset of clinical tolerance to milk protein. J. Allergy Clin. Immunol. 123:43-52
57. + T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J. Allergy Clin. Immunol. 111:862-868
58. + T-regulatory cells in both nonatopic and atopic individuals. J. Allergy Clin. Immunol. 120:429-436
59. + T cells depends on allergen concentration, type of allergen and atopy status of the donor. Immunology 116:103-111
60. Arnon R, van Regenmortel MHV. 1992. Structural basis of antigen specificity and design of new vaccines. FASEB J. 6:3265-3274
61. Greene WK, Cyster JG, Chua KY, O'Brien RM, Thomas WR. 1991. IgE and IgG binding of peptides expressed from fragments of cDNA encoding the major house dust mite allergen Der p I. J. Immunol. 147:3768-3773
62. van't Hof W, Driedijk PC, van den Berg M, Beck-Sickinger AG, Jung G, Aalberse RC. 1991. Epitope mapping of the Dermatophagoides pteronyssinus house dust mite major allergen Der p II using overlapping synthetic peptides. Mol. Immunol. 28:1225-32
63. Ball T, Vrtala S, Sperr WR, Valent P, Susani M, et al. 1994. Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. J. Biol. Chem. 269:28323-28328
64. van Milligen FJ, van't Hof W, van den Berg M, Aalberse RC. 1994. IgE epitopes on the cat (Felis domesticus) major allergen Fel d I: a study with overlapping synthetic peptides. J. Allergy Clin. Immunol. 93:34-43
65. 2+. EMBO J. 13:3481-3486
66. Engel E, Richter K, Obermeyer G, Briza P, Kungl AJ, et al. 1997. Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains. J. Biol. Chem. 272:28630-28637
67. Westritschnig K, Focke M, Verdino P, Goessler W, Keller W, et al. 2004. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J. Immunol. 172:5684-92
68. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, et al. 1997. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J. Clin. Investig. 99:1673-1681
69. Gieras A, Focke-Tejkl M, Ball T, Verdino P, Hartl A, et al. 2007. Molecular determinants of allergen-induced effector cell degranulation. J. Allergy Clin. Immunol. 119:384-390
70. Christensen LH, HolmJ, Lund G, RiiseE, LundK. 2008. Several distinct properties ofthe IgE repertoire determine effector cell degranulationin response to allergen challenge. J. Allergy Clin. Immunol. 122:298-304
71. Niemi M, Jylhä S, Laukkanen ML, Söderlund H, Mäkinen-KiljunenS, et al. 2007. Molecular interactions between a recombinant IgE antibody and the beta-lactoglobulin allergen. Structure 15:1413-1421
72. Padavattan S, Flicker S, Schirmer T, Madritsch C, Randow S, et al. 2009. High-affinity IgE recognition of a conformational epitope of the major respiratory allergen Phl p 2as revealedby X-ray crystallography. J. Immunol. 182:2141-2151
73. Fedorov AA, Ball T, Mahoney NM, Valenta R, Almo SC. 1997. The molecular basis for allergen cross-reactivity: crystal structure and IgE-epitope mapping of birch pollen profilin. Structure 5:33-45
74. Flicker S, Vrtala S, Steinberger P, Vangelista L, Bufe A, et al. 2000. A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope-containing domain. J. Immunol. 165:3849-59
75. Flicker S, Steinberger P, Ball T, Krauth MT, Verdino P, et al. 2006. Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity. J. Allergy Clin. Immunol. 117:1336-43
76. van Neerven RJ, Knol EF, Ejrnaes A, Wü rtzen PA. 2006. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int. Arch. Allergy Immunol. 141:119-129
77. Wachholz PA, Durham SR. 2004. Mechanisms of immunotherapy: IgG revisited. Curr. Opin. Allergy Clin. Immunol. 4:313-318
78. Flicker S, Valenta R. 2003. Renaissance of the blocking antibody concept in type I allergy. Int. Arch. Allergy Immunol. 132:13-24
79. Visco V, Dolecek C, Denépoux S, Le Mao J, Guret C, et al. 1996. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J. Immunol. 157:956-962
80. Denépoux S, Eibensteiner PB, Steinberger P, Vrtala S, Visco V, et al. 2000. Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Lett. 465:39-46
81. Daeron M, Malbec O, Latour S, Arock M, Fridman WH. 1995. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J. Clin. Investig. 95:577-585
82. Saxon A, Zhu D, Zhang K, Allen LC, Kepley CL. 2004. Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases. Curr. Opin. Allergy Clin. Immunol. 4:563-568
83. Ejrnaes AM, Svenson M, Lund G, Larsen JN, Jacobi H. 2006. Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy-induced serum immunoglobulin G: no evidence that FcγRIIB signalling is important. Clin. Exp. Allergy 36:273-282
84. Sellge G, Laffer S, Mierke C, Vrtala S, Hoffmann MW, et al. 2005. Development of an in vitro system for the study of allergens and allergen-specific immunoglobulin E and immunoglobulin G: Fcε receptor I supercross-linking is a possible new mechanism of immunoglobulin G-dependent enhancement of type I allergic reactions. Clin. Exp. Allergy 35:774-781
85. Aghayan-Ugurluoglu R, Ball T, Vrtala S, Schweiger C, Kraft D, Valenta R. 2000. Dissociationofallergen-specific IgE and IgA responses in sera and tearsof pollen-allergic patients:astudy performed with purified recombinant pollen allergens. J. Allergy Clin. Immunol. 105:803-813
86. Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, et al. 1999. B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J. 13:1277-90
87. Horst A, Hunzelmann N, Arce S, Herber M, Manz RA, et al. 2002. Detection and characterization of plasma cells in peripheral blood: correlation of IgE+ plasma cell frequency with IgE serum titre. Clin. Exp. Immunol. 130:370-378
88. Steinberger P, Kraft D, Valenta R. 1996. Construction of a combinatorial IgE library from an allergic patient. Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5. J. Biol. Chem. 271:10967-72
89. van der Stoep N, van der Linden J, Logtenberg T. 1993. Molecular evolution of the human immunoglob-ulinEresponse: high incidenceof shared mutations and clonal relatedness among epsilon VH5 transcripts from three unrelated patients with atopic dermatitis. J. Exp. Med. 177:99-107
90. Snow RE, Chapman CJ, Frew AJ, Holgate ST, Stevenson FK. 1995. Analysis of Ig VH region genes encoding IgE antibodies in splenic B lymphocytes of a patient with asthma. J. Immunol. 154:5576-5581
91. Coker HA, Harries HE, Banfield GK, Carr VA, Durham SR, et al. 2005. Biased use ofVH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J. Allergy Clin. Immunol. 116:445-452
92. Eibensteiner P, Spitzauer S, Steinberger P, Kraft D, Valenta R. 2000. Immunoglobulin E antibodies of atopic individuals exhibit a broad usage of VH-gene families. Immunology 101:112-119
93. Davies JM, O'Hehir RE. 2004. VH gene usage in immunoglobulin E responses of seasonal rhinitis patients allergic to grass pollen is oligoclonal and antigen driven. Clin. Exp. Allergy 34:429-436
94. Lim A, Luderschmidt S, Weidinger A, Schnopp C, Ring J, et al. 2007. The IgE repertoire in PBMCs of atopic patients is characterized by individual rearrangements without variable region of the heavy immunoglobulin chain bias. J. Allergy Clin. Immunol. 120:696-706
95. Andréasson U, Flicker S, Lindstedt M, Valenta R, Greiff L, et al. 2006. The human IgE-encoding transcriptome to assess antibody repertoires and repertoire evolution. J. Mol. Biol. 362:212-227
96. Yamaguchi M, Sayama K, Yano K, Lantz CS, Noben-Trauth N, et al. 1999. IgE enhances Fcε receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fcε receptor I expression and mediator release. J. Immunol. 162:5455-5465
97. Asai K, Kitaura J, Kawakami Y, Yamagata N, Tsai M, et al. 2001. Regulation of mast cell survival by IgE. Immunity 14:791-800
98. Kalesnikoff J, Huber M, Lam V, Damen JE, Zhang J, et al. 2001. Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity 14:801-811
99. Katoh N, Kraft S, Wessendorf JH, Bieber T. 2000. The high-affinity IgE receptor (FcεRI) blocks apoptosis in normal human monocytes. J. Clin. Investig. 105:183-190
100. Linhart B, Bigenzahn S, Hartl A, Lupinek C, Thalhamer J, et al. 2007. Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J. Immunol. 178:3924-3931
101. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, et al. 2003. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted im-munoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy 33:1198-1208
102. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, et al. 2004. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA 101:14677-14682
103. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, et al. Immune Tolerance Network Group. 2006. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355:1445-1455
104. Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H, et al. 1996. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J. Exp. Med. 183:599-609
105. Focke M, Linhart B, Hartl A, Wiedermann U, Sperr WR, et al. 2004. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin. Exp. Allergy 34:1525-1533
106. Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, et al. 2001. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 15:2042-44
107. van Neerven RJ, Ebner C, Yssel H, Kapsenberg ML, Lamb JR. 1996. T-cell responses to allergens: epitope-specificity and clinical relevance. Immunol. Today 17:526-532
108. Larche M. 2007. Update on the current status of peptide immunotherapy. J. Allergy Clin. Immunol. 119:906-909
109. Haselden BM, Kay AB, Larche M. 1999. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189:1885-1894
110. Campana R, Mothes N, Rauter I, Vrtala S, Reininger R, et al. 2008. Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J. Allergy Clin. Immunol. 121:528-530
111. Valenta R 2002. The future of antigen-specific immunotherapy of allergy. Nat. Rev. Immunol. 2:446-453
112. Focke M, Swoboda I, Marth K, Valenta R 2009. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific IgE and T cell reactivity. Clin. Exp. Allergy. In press
113. Siskind GW, Paul WE, Benacerraf B. 1966. Studies on the effect of the carrier molecule on antihapten antibody synthesis. I. Effect of carrier on the nature of the antibody synthesized. J. Exp. Med. 123:673-688
114. Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, et al. 2009. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J. Immunol. 182:6298-306
115. Maurer D, Fiebiger S, Ebner C, Reininger B, Fischer GF, et al. 1996. Peripheral blood dendritic cells express FceRI as a complex composed of FceRIa-and FceRIy-chains and can use this receptor for IgE-mediated allergen presentation. J. Immunol. 157:607-616
116. GreweM, GyufkoK, Schopf E, Krutmann J. 1994. Lesional expression of interferon-y in atopic eczema. Lancet 343:25-26
117. Werfel T, Morita A, Grewe M, Renz H, Wahn U, et al. 1996. Allergen specificity of skin-infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic dermatitis. J. Investig. Dermatol. 107:871-876
118. Hoffmann-Sommergruber K, Ferreira ED, Ebner C, Barisani T, Korninger L, et al. 1996. Detection of allergen-specific IgE in tears of grass pollen-allergic patients with allergic rhinoconjunctivitis. Clin. Exp. Allergy 26:79-87
119. Westritschnig K, Horak F, Swoboda I, Balic N, Spitzauer S, et al. 2008. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur. J. Clin. Investig. 38:260-267
120. Valenta R, Duchene M, Pettenburger K, Sillaber C, Valent P, et al. 1991. Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 253:557-560
121. Valenta R, Duchene M, Ebner C, Valent P, Sillaber C, et al. 1992. Profilins constitute a novel family of functional plant pan-allergens. J. Exp. Med. 175:377-385
122. Reese G, Ayuso R, Lehrer SB. 1999. Tropomyosin: an invertebrate pan-allergen. Int. Arch. Allergy Immunol. 119:247-258
123. Valenta R, Hayek B, Seiberler S, Bugajska-Schretter A, Niederberger V, et al. 1998. Calcium-binding allergens: from plants to man. Int. Arch. Allergy Immunol. 117:160-166
124. Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM, et al. 2002. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J. 16:414-416
125. Harwanegg C, Laffer S, Hiller R, Mueller MW, Kraft D, et al. 2003. Microarrayed recombinant allergens for diagnosis of allergy. Clin. Exp. Allergy 33:7-13
126. Valenta R, Niederberger V. 2007. Recombinant allergens for immunotherapy. J. Allergy Clin. Immunol. 119:826-830
127. Purohit A, Laffer S, Metz-Favre C, Verot A, Kricek F, et al. 2005. Poor association between allergen-specific serum immunoglobulin E levels, skin sensitivity and basophil degranulation: a study with recom-binant birch pollen allergen Bet v 1 and an immunoglobulin E detection system measuring immunoglob-ulin E capable of binding to FceRI. Clin. Exp. Allergy 35:186-192
128. van Ree R. 2002. Carbohydrate epitopes and their relevance for the diagnosis and treatment of allergic diseases. Int. Arch. Allergy Immunol. 129:189-197
129. Mari A, Ooievaar-de Heer P, Scala E, Giani M, Pirrotta L, Zuidmeer L, et al. 2008. Evaluation by double-blind placebo-controlled oral challenge of the clinical relevance of IgE antibodies against plant glycans. Allergy 63:891-896
130. Valenta R, Mittermann I, Werfel T, Garn H, Renz H. 2009. Linking allergy to autoimmune disease. Trends Immunol. 30:109-116
131. Hewitt CR, Brown AP, Hart BJ, Pritchard DI. 1995. A major house dust mite allergen disrupts the immunoglobulin E network by selectively cleaving CD23: innate protection by antiproteases. J. Exp. Med. 182:1537-1544
132. Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, et al. 1999. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J. Clin. Investig. 104:123-33
133. Vrtala S, Akdis CA, Budak F, Akdis M, Blaser K, et al. 2000. T cell epitope-containing hypoallergenic recombinant fragmentsofthe major birch pollen allergen, Betv1, induce blocking antibodies. J. Immunol. 165:6653-6659
134. Korematsu S, Tanaka Y, Hosoi S, Koyanagi S, Yokota T, et al. 2000. C8/119S mutation of major mite allergen Derf-2 leads todegenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J. Immunol. 165:2895-2902
135. Shreffler WG, Castro RR, Kucuk ZY, Charlop-Powers Z, Grishina G, et al. 2006. The major glyco-protein allergen from Arachis hypogaea, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. J. Immunol. 177:3677-3685
136. Wallner BP, Gefter ML. 1996. Peptide therapy for treatment of allergic diseases. Clin. Immunol. Im-munopathol. 80:105-109
137. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. 1983. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J. Exp. Med. 157:1434-1447
138. Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. 1993. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc. Natl. Acad. Sci. USA 90:7608-7612
139. Norman PS, Ohman JL, Jr, Long AA, Creticos PS, Gefter MA, et al. 1996. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 154:1623-1628
140. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. 1996. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int. Immunol. 8:1937-1945
141. Pene J, Desroches A, Paradis L, Lebel B, Farce M, et al. 1998. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J. Allergy Clin. Immunol. 102:571-578
142. Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, et al. 1998. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101:747-754
143. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. 1999. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin. Immunol. 93:222-231
144. Haselden BM, Larche M, Meng Q, Shirley K, Dworski R, et al. 2001. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J. Allergy Clin. Immunol. 108:394-401
145. Oldfield WL, Kay AB, Larche M. 2001. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol. 167:1734-1739
146. Oldfield WL, Larche M, Kay AB. 2002. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 360:47-53
147. Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, et al. 2003. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J. Allergy Clin. Immunol. 111:854-861
148. Ali FR, Oldfield WL, HigashiN, LarcheM, Kay AB. 2004. Late asthmatic reactions inducedbyinhalation of allergen-derived T cell peptides. Am. J. Respir. Crit. Care Med. 169:20-26
149. + T cells: a double-blind placebo-controlled study. Allergy 59:1097-1101
150. + T cell population with regulatory activity. PLoS Med. 2:e78
151. + T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin. Exp. Allergy 35:52-58
152. Alexander C, Tarzi M, Larche M, Kay AB. 2005. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 60:1269-1274
153. Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, et al. 2006. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin. Exp. Allergy 36:465-474
154. Faith A, Akdis CA, Akdis M, Joss A, Wymann D, Blaser K. 1999. An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling. J. Immunol. 162:1836-1842
155. Valenta R, Vrtala S, Focke-Tejkl M, Bugajska S, Ball T, et al. 1999. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy. Biol. Chem. 380:815-824
156. Linhart B, Valenta R. 2005. Molecular design of allergy vaccines. Curr. Opin. Immunol. 17:646-655
157. Ferreira F, Briza P, Infuhr D, Schmidt G, Wallner M, et al. 2006. Modified recombinant allergens for safer immunotherapy. Inflamm. Allergy Drug Targets 5:5-14
158. Wallner M, Stocklinger A, Thalhamer T, Bohle B, Vogel L, et al. 2007. Allergy multivaccines created by DNA shuffling of tree pollen allergens. J. Allergy Clin. Immunol. 120:374-380
159. Gafvelin G, Parmley S, Neimert-Andersson T, Blank U, Eriksson TL, et al. 2007. Hypoallergens for allergen-specific immunotherapy bydirected molecular evolutionofmite group2allergens. J. Biol. Chem. 282:3778-3787
160. Westritschnig K, Linhart B, Focke-Tejkl M, Pavkov T, Keller W, et al. 2007. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. J. Immunol. 179:7624-34
161. Mothes-Luksch N, Stumvoll S, Linhart B, Focke M, Krauth MT, et al. 2008. Disruption of allergenic activity ofthe major grass pollen allergen Phlp2 byreassemblyasa mosaic protein. J. Immunol. 181:4864-4873
162. Kahlert H, Suck R, Weber B, Nandy A, Wald M, et al. 2008. Characterization of a hypoallergenic re-combinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int. Arch. Allergy Immunol. 145:193-206
163. Vrtala S, Focke-Tejkl M, Swoboda I, Kraft D, Valenta R. 2004. Strategies for converting allergens into hypoallergenic vaccine candidates. Methods 32:313-320
164. Klimek L, Bachert C, Doemer C, Meyer H, Narkus A. 2005. Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious. Allergy Clin. Immunol. Int. 2005(Suppl. 1):15
165. Rak S. 2009. Clinical results with a hypoallergenic recombinant birch pollen allergen derivative. Presented at 27th Congr., EAACI 2009, Warsaw, June 6-10
166. Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, et al. 2005. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J. Allergy Clin. Immunol. 116:347-354
167. Pree I, Reisinger J, Focke M, Vrtala S, Pauli G, et al. 2007. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J. Immunol. 179:5309-5316
168. Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, et al. 2008. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin. Exp. Allergy 38:1514-1525
169. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749
170. Weiss R, Scheiblhofer S, Gabler M, Ferreira F, Leitner WW, Thalhamer J. 2006. Is genetic vaccination against allergy possible? Int. Arch. Allergy Immunol. 139:332-345
171. Raz E, Tighe H, Sato Y, Corr M, Dudler JA, et al. 1996. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. Sci. USA 93:5141-5145
172. Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, et al. 1996. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat. Med. 2:540-544
173. Weiss R, Scheiblhofer S, Freund J, Ferreira F, Livey I, Thalhamer J. 2002. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 20:3148-3154
174. Roy K, Mao HQ, Huang SK, Leong KW. 1999. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5:387-391
175. Toda M, Sato H, Takebe Y, Taniguchi Y, Saito S, et al. 2000. Inhibition of immunoglobulin E response to Japanese cedar pollen allergen (Cry j 1) in mice by DNA immunization: different outcomes dependent on the plasmid DNA inoculation method. Immunology 99:179-186
176. Slater JE, Paupore E, Zhang YT, Colberg-Poley AM. 1998. The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J. Allergy Clin. Immunol. 102:469-475
177. Bauer R, Scheiblhofer S, Kern K, Gruber C, Stepanoska T, et al. 2006. Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. J. Allergy Clin. Immunol. 118:269-276
178. Hochreiter R, Stepanoska T, Ferreira F, Valenta R, Vrtala S, et al. 2003. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen. Eur. J. Immunol. 33:1667-1676
179. Chapman MD, FerreiraF, VillalbaM, CromwellO, BryanD, et al. 2008. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J. Allergy Clin. Immunol. 122:882-889
180. Niederberger V, Pauli G, Gronlund H, Froschl R, Rumpold H, et al. 1998. Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. J. Allergy Clin. Immunol. 102:579-591
181. Gronlund H, Bergman T, Sandstrom K, Alvelius G, Reininger R, et al. 2003. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J. Biol. Chem. 278:40144-40151
182. Westritschnig K, Horak F, Swoboda I, Balic N, Spitzauer S, et al. 2008. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur. J. Clin. Investig. 38:260-267
183. Weghofer M, Thomas WR, Kronqvist M, Mari A, Purohit A, et al. 2008. Variability of IgE reactivity profiles among European mite allergic patients. Eur. J. Clin. Investig. 38:959-965
184. Focke M, Marth K, Flicker S, Valenta R. 2008. Heterogeneity of commercial timothy grass pollen extracts. Clin. Exp. Allergy 38:1400-1408
185. King TP, Jim SY, Monsalve RI, Kagey-Sobotka A, Lichtenstein LM, Spangfort MD. 2001. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J. Immunol. 166:6057-6065
186. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, et al. 2002. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J. 16:1301-1303
187. Linhart B, Hartl A, Jahn-Schmid B, Verdino P, Keller W, et al. 2005. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol. 115:1010-1016
188. Linhart B, Mothes-Luksch N, Vrtala S, Kneidinger M, Valent P, Valenta R. 2008. Ahypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6. Biol. Chem. 389:925-933
189. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. 2005. Allergen-specific immunotherapy with recombinant grass pollen allergens. J. Allergy Clin. Immunol. 116:608-613
190. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, et al. 2008. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 122:951-960
191. Bracy JL, Sachs DH, Iacomini J. 1998. Inhibition of xenoreactive natural antibody production by retro-viral gene therapy. Science 281:1845-1847
192. Steptoe RJ, Ritchie JM, Harrison LC. 2003. Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J. Clin. Investig. 111:1357-1363
193. Alderuccio F, Murphy K, Toh BH. 2003. Stem cells engineered to express self-antigen to treat autoim-munity. Trends Immunol. 24:176-180
194. Baranyi U, Linhart B, Pilat N, Gattringer M, Bagley J, et al. 2008. Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells. J. Immunol. 180:8168-8175
195. Host A, Jacobsen HP, Halken S, Holmenlund D. 1995. The natural history of cow's milk protein allergy/intolerance. Eur. J. Clin. Nutr. 49(Suppl. 1):S13-18
196. David MF. 1977. Prevention of homocytotropic antibody formation and anaphylactic sensitization by prefeeding antigen. J. Allergy Clin. Immunol. 60:180-187
197. Holt PG, Vines J, Britten D. 1988. Sublingual allergen administration. I. Selective suppression of IgE production in rats by high allergen doses. Clin. Allergy 18:229-234
198. Zemann B, Schwaerzler C, Griot-Wenk M, Nefzger M, Mayer P, et al. 2003. Oral administration of specific antigens to allergy-prone infant dogs induces IL-10 and TGF-β expression and prevents allergy in adult life. J. Allergy Clin. Immunol. 111:1069-1075
199. Wiedermann U, Jahn-Schmid B, Bohle B, Repa A, Renz H, et al. 1999. Suppression of antigen-specific T-and B-cell responses by intranasal or oral administration of recombinant bet v 1, the major birch pollen allergen, in a murine model of type I allergy. J. Allergy Clin. Immunol. 103:1202-1210
200. + T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 61:173-180
201. Wiedermann U, Herz U, Baier K, Vrtala S, Neuhaus-Steinmetz U, et al. 2001. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice. Int. Arch. Allergy Immunol. 126:68-77
202. Astori M, von Garnier C, Kettner A, Dufour N, Corradin G, Spertini F. 2000. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J. Immunol. 165:3497-3505
203. Jarnicki AG, Tsuji T, Thomas WR. 2001. Inhibition of mucosal and systemic T(h)2-type immune responses by intranasal peptides containing a dominant T cell epitope of the allergen Der p 1. Int. Immunol. 13:1223-31
204. Marazuela EG, Rodriguez R, Fernández-Garçia H, Garçia MS, Villalba M, Batanero E. 2008. Intranasal immunization with a dominant T-cell epitope peptide of a major allergen of olive pollen prevents mice from sensitization to the whole allergen. Mol. Immunol. 45:438-445
205. Hufnagl K, Winkler B, Focke M, Valenta R, Scheiner O, et al. 2005. Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. J. Allergy Clin. Immunol. 116:370-376
206. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. 2006. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117:802-809
207. Muraro A, Dreborg S, Halken S, HostA, NiggemannB, et al. 2004. Dietary preventionofallergic diseases in infants and small children. Part I: immunologic background and criteria for hypoallergenicity. Pediatr. Allergy Immunol. 15:103-111
208. Takagi H, Hiroi T, Yang L, Takamura K, Ishimitsu R, et al. 2008. Efficient induction of oral tolerance by fusing cholera toxin B subunit with allergen-specific T-cell epitopes accumulated in rice seed. Vaccine 26:6027-6030
209. Huibregtse IL, Snoeck V, de Creus A, Braat H, De Jong EC, et al. 2007. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 133:517-528
210. Segal DM, Taurog JD, Metzger H. 1977. Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation. Proc. Natl. Acad. Sci. USA 74:2993-2997
211. Malley A, Perlman F. 1970. Timothy pollen fractions in treatment of hay fever. I. Clinical and immuno-logical response to small and higher molecular weight fractions. J. Allergy 45:14-29
212. Malley A, Campbell DH, Heimlich EM. 1964. Isolation and immunochemical properties of haptenic material from Timothy Pollen. J. Immunol. 93:420-425
213. Ganglberger E, Sponer B, Schöll I, Wiedermann U, Baumann S, et al. 2001. Monovalent fusion proteins of IgE mimotopes are safe for therapy of type I allergy. FASEB J. 15:2524-2526
214. Suphioglu C, Schäppi G, Kenrick J, Levy D, Davies JM, O'Hehir RE. 2001. A novel grass pollen allergen mimotope identified by phage display peptide library inhibits allergen-human IgE antibody interaction. FEBS Lett. 502:46-52
215. Lee WY, Sehon AH. 1977. Abrogation of reaginic antibodies with modified allergens. Nature267:618-619
216. Sato Y, Roman M, Tighe H, Lee D, Corr M, et al. 1996. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352-354
217. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1623-1631
218. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, et al. 2000. Conjugation of immuno-stimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106:124-134
219. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, et al. 2004. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113:235-241
220. Bohle B, Breitwieser A, Zwolfer B, Jahn-Schmid B, Sara M, et al. 2004. A novel approach to specific allergy treatment: the recombinant fusion protein ofabacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J. Immunol. 172:6642-6648
221. Hulse KE, Reefer AJ, Engelhard VH, Satinover SM, Patrie JT, et al. 2008. Targeting Fel d 1 to FcγRI induces a novel variation of the T(H)2 response in subjects with cat allergy. J. Allergy Clin. Immunol. 121:756-762
222. Zhu D, Kepley CL, Zhang K, Terada T, YamadaT, Saxon A. 2005. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat. Med. 11:446-449
223. Mart́inez-Gömez JM, Johansen P, Rose H, Steiner M, Senti G, et al. 2009. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 64:172-178
224. Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, et al. 2006. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol. 117:1470-76
225. Valenta R, Duchene M, Vrtala S, Birkner T, Ebner C, et al. 1991. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J. Allergy Clin. Immunol. 88:889-894
226. Valenta R, Vrtala S, Ebner C, Kraft D, Scheiner O. 1992. Diagnosis of grass pollen allergy with recom-binant timothy grass (Phleum pratense) pollen allergens. Int. Arch. Allergy Immunol. 97:287-294
227. Ebner C, Szepfalusi Z, Ferreira F, Jilek A, Valenta R, et al. 1993. Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides. J. Immunol. 150:1047-1054 (Pubitemid 23133685)
228. Joost van Neerven R, van t' Hof W, Ringrose JH, Jansen HM, Aalberse RC, et al. 1993. T cell epitopes of house dust mite major allergen Der p II. J. Immunol. 151:2326-2335
229. Sehon LZ, Mohapatra SS. 1992. Induction of IgE antibodies in mice with recombinant grass pollen antigens. Immunology 76:158-163
230. Zhang L, Mohapatra SS. 1993. Antigen-and isotype-specific immune responses to a recombinant antigen-allergen chimeric (RAAC) protein. J. Immunol. 151:791-799
231. Ferreira FD, Mayer P, Sperr WR, Valent P, Seiberler S, et al. 1996. Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. J. Allergy Clin. Immunol. 97:95-103 (Pubitemid 26045973)
232. Vrtala S, Mayer P, Ferreira F, Susani M, Sehon AH, et al. 1996. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2. J. Allergy Clin. Immunol. 98:913-921 (Pubitemid 26405891)
233. Breiteneder H, Ferreira F, Hoffmann-Sommergruber K, Ebner C, Breitenbach M, et al. 1993. Four re-combinant isoforms of Cor a I, the major allergen of hazel pollen, show different IgE-binding properties. Eur. J. Biochem. 212:355-362
234. Smith AM, Chapman MD. 1996. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol. Immunol. 33:399-405
235. Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, et al. 1997. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat. Biotechnol. 15:754-758
236. Zeiler T, Taivainen A, Rytkonen M, Rautiainen J, Karjalainen H, et al. 1997. Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J. Allergy Clin. Immunol. 100:721-727
237. Moser M, Crameri R, Brust E, Suter M, Menz G. 1994. Diagnostic value of recombinant Aspergillus fumigatus allergen I/a for skin testing and serology. J. Allergy Clin. Immunol. 93:1-11
238. Menz G, Dolecek C, Schonheit-Kenn U, Ferreira F, Moser M, et al. 1996. Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen. Clin. Exp. Allergy 26:50-60 (Pubitemid 26036135)
239. Pauli G, Oster JP, Deviller P, Heiss S, Bessot JC, et al. 1996. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: diagnostic value for birch pollen and associated allergies. J. Allergy Clin. Immunol. 97:1100-1109
240. Gajhede M, Osmark P, Poulsen FM, Ipsen H, Larsen JN, et al. 1996. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nat. Struct. Biol. 3:1040-1045
241. van Hage-Hamsten M, Kronqvist M, Zetterstrom O, Johansson E, Niederberger V, et al. 1999. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J. Allergy Clin. Immunol. 104:969-977
242. Pauli G, Purohit A, Oster JP, De Blay F, Vrtala S, et al. 2000. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin. Exp. Allergy 30:1076-1084